Pharmaceuticals

Arthritic Therapeutic Market Trends 2026–2030 Identifying Emerging Business Opportunities

April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Arthritic Therapeutic Market During 2026–2030?

The arthritic therapeutic market size has experienced significant growth in recent years. It is anticipated to expand from $72.44 billion in 2025 to $77 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.3%. This historical expansion can be attributed to the increasing global prevalence of arthritis, a growing geriatric population, restricted access to advanced therapeutics, heightened awareness of arthritis management, and the development of hospital and clinic infrastructure.

The arthritic therapeutic market size is anticipated to experience substantial expansion over the coming years. This market is projected to reach $97.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.0%. This forecasted growth can be linked to several factors, including the emergence of novel biologics and targeted therapies, the wider uptake of telemedicine and remote patient monitoring, the incorporation of digital health platforms, increased funding for arthritis research and clinical trials, and the advancement of personalized medicine strategies for arthritis. Key developments expected during this period involve a greater embrace of biologic and targeted treatments for arthritis, a growing inclination towards customized arthritis management plans, an increase in home-based physical therapy and rehabilitation offerings, the proliferation of online pharmacies and digital distribution channels, and an enhanced emphasis on early diagnosis and proactive arthritis prevention.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19297&type=smp

What Underlying Factors Are Accelerating The Growth Of The Arthritic Therapeutic Market?

A rising occurrence of arthritis is projected to drive expansion within the arthritic therapeutic market in the coming period. Arthritis encompasses over 100 different conditions, predominantly marked by discomfort and swelling in the joints. The frequency of arthritis is escalating, attributable to an aging demographic, higher rates of obesity, and lifestyle elements that exacerbate joint strain and inflammation. Treatments for arthritis relieve discomfort, diminish inflammation, and enhance joint mobility, thereby improving the general well-being of individuals afflicted. As an illustration, in June 2024, a report from the Australian Institute of Health and Welfare, an Australia-based government organization, indicated that around 514,000 people (2.0% of the population) had rheumatoid arthritis in 2022. Rheumatoid arthritis constituted 2.0% of the aggregate disease burden and accounted for 16% of the total burden across all musculoskeletal conditions in 2023. Consequently, the rising prevalence of arthritis is fueling the expansion of the arthritic therapeutic market.

How Are The Various Segments Of The Arthritic Therapeutic Market Categorized?

The arthritic therapeutic market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Xanthine Oxidase Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Type: Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout, Other Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab

2) By Interleukin Inhibitors: Interleukin-6 (IL-6) Inhibitors, Interleukin-1 (IL-1) Inhibitors, Interleukin-17 (IL-17) Inhibitors, Interleukin-23 (IL-23) Inhibitors

3) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam

4) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

5) By Xanthine Oxidase Inhibitors: Allopurinol, Febuxostat

6) By Other Drug Classes: Disease-Modifying Antirheumatic Drugs (DMARDs), Janus Kinase (JAK) Inhibitors, Biologic DMARDs, Topical Analgesics, Opioid Pain Medications

What Trends Are Affecting The Expansion Of The Arthritic Therapeutic Market?

Leading firms within the arthritis therapeutic sector are concentrating on creating novel solutions, including biosimilar monoclonal antibody-derived treatments, with the aim of improving treatment effectiveness and lowering expenses. These biosimilar monoclonal antibody treatments are specifically engineered to closely imitate the efficacy of their original counterparts, thereby providing comparable health advantages at a potentially reduced price point. As an example, in May 2024, Bio-Thera Solutions Ltd., a biopharmaceutical firm from China, introduced TOFIDENCE, an intravenous biosimilar monoclonal antibody product derived from ACTEMRA. TOFIDENCE (tocilizumab-bavi) has been developed as a biosimilar to the reference medication ACTEMRA and has received approval for addressing moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Which Major Firms Influence Developments In The Arthritic Therapeutic Market?

Major companies operating in the arthritic therapeutic market are Pfizer Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Pharma AB, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Zimmer Biomet Holdings Inc., UCB Pharma S.A., Incyte Corporation, Celltrion Inc., Mallinckrodt Pharmaceuticals, Genentech Inc., Anika Therapeutics Inc., Medac GmbH

Read the full arthritic therapeutic market report here:

https://www.thebusinessresearchcompany.com/report/arthritic-therapeutic-global-market-report

Which Region Is Projected To Dominate The Arthritic Therapeutic Market During The Forecast Period?

North America was the largest region in the arthritic therapeutic market in 2025. The regions covered in the arthritic therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Arthritic Therapeutic Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19297&type=smp

Browse Through More Reports Similar to the Global Arthritic Therapeutic Market 2026, By The Business Research Company

Mantle Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mantle-cell-lymphoma-therapeutics-global-market-report

Glycomic Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Pruritus Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795